Breast - Invasive lobular carcinoma with TOPO2A positivity in 5-10% of tumor cells.
Colon - Colorectal adenocarcinoma with TOPO2A immunostaining in >50% of tumor cells.
Esophagus - Adenocarcinoma with TOPO2A positivity of >60% of tumor cells.
Esophagus - Squamous cell carcinoma with TOPO2A positivity in about 20% of tumor cells.
Kidney - Clear cell renal cell carcinoma with TOPO2A positivity of 1-2% of tumor cells.
Kidney - Oncocytoma showing TOPO2A immunostaining in <1% of tumor cells.
Kidney - Papillary renal cell carcinoma with TOPO2A immunostaining in 1-2% of tumor cells.
Oral cavity - Squamous cell carcinoma with TOPO2A positivity in 20-30% of tumor cells.
Ovary - Clear cell carcinoma with TOPO2A positivity in about 10% of tumor cells.
Ovary - Serous high-grade carcinoma with TOPO2A positivity in about 10-15% of tumor cells.
Pharynx - Squamous cell carcinoma with TOPO2A positivity in <10% of tumor cells.
Prostate - Adenocarcinoma (Gleason 3+3=6) with TOPO2A immunostaining in 1-3% of tumor cells.
Thyroid - Follicular carcinoma with TOPO2A immunostaining in about 1% of tumor cells.
Urinary bladder - Muscle-invasive urothelial carcinoma showing TOPO2A immunostaining in 60-75% of tumor cells.